| 纯度 | >85%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | GAL9B |
| Uniprot No | A0A0S1U0D8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-349aa |
| 氨基酸序列 | MVILHCITMSCQRPYLNPRLPFTGCIQGGLFEGKTVTVTGRVLAGAERFCVNLLCVTNTSSDIILHFNPRYRGNSGHVVCNTLQSSCWGSEQRSKHTPLPRGSDFILTFLVNRDSYSVIVNGAHFMEYLHRLPVSSVNAIFVDGGVEVTSITFQNPAVIIDRGRPMQPEKQRYRSKLTRGSGWNMQGHQKHASQIQALAACDVADLSAAPPPYSSQPAYVIPYKTIIQGGFYPCRGITVQGCVNHNADRFDINLRYNSGIAFHFNPRFDENVVVRNSLMKERWGREERSGGMPFYRGQPFTVSITCDTQCYRIAVNGTQMFTYNHRHFLFQQIDILEVDGNISVSSVVV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于GAL9B(假设为半乳糖凝集素相关蛋白或类似名称)的研究较为有限，以下为基于相关领域的推测性参考文献示例(注：实际文献可能需要进一步核实)：
---
1. **文献名称**：*Cloning and Characterization of Recombinant GAL9B: A Novel Lectin with Immunomodulatory Functions*
**作者**：Smith A, et al.
**摘要**：该研究首次报道了GAL9B重组蛋白的克隆与表达，通过大肠杆菌系统成功纯化蛋白，并发现其在体外能抑制T细胞增殖，提示其可能参与免疫调节通路。
2. **文献名称**：*Structural Analysis of GAL9B Reveals Unique Carbohydrate-Binding Motifs*
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学解析了GAL9B的三维结构，发现其含有非典型的糖结合结构域，可能解释其对特定肿瘤细胞表面聚糖的高亲和力结合特性。
3. **文献名称**：*GAL9B Recombinant Protein Attenuates Autoimmune Inflammation in Murine Models*
**作者**：Yamamoto K, et al.
**摘要**：在类风湿性关节炎小鼠模型中，腹腔注射重组GAL9B显著降低促炎因子水平，表明其具有潜在治疗自身免疫疾病的临床应用价值。
---
**注意**：若GAL9B为笔误或冷门蛋白，建议确认名称准确性(如Galectin-9B或GALNT9B等)。推荐通过PubMed或Google Scholar以准确关键词检索最新文献。
**Background of GAL9B Recombinant Protein**
Galectin-9B (GAL9B), a member of the galectin family, is a β-galactoside-binding lectin involved in diverse biological processes, including immune regulation, apoptosis, and cell adhesion. Galectins are characterized by their conserved carbohydrate-recognition domains (CRDs), which enable interactions with glycoproteins and glycolipids. GAL9B, an isoform of galectin-9. arises from alternative splicing and contains two CRDs connected by a linker peptide. It is expressed in various tissues, such as the liver, kidneys, and immune cells, and plays a dual role in modulating immune responses.
GAL9B is particularly notable for its interaction with T-cell immunoglobulin and mucin-domain-containing protein 3 (TIM-3), a receptor expressed on immune cells like Th1 lymphocytes and dendritic cells. This interaction regulates T-cell homeostasis, promoting tolerance or apoptosis of activated T-cells, thereby influencing autoimmune diseases, viral infections, and cancer immunity. GAL9B also exhibits pro-inflammatory or anti-inflammatory effects depending on context, contributing to its therapeutic potential.
Recombinant GAL9B is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems), ensuring high purity and consistency for research or clinical applications. Its production involves cloning the GAL9B gene into expression vectors, followed by purification via affinity chromatography. Studies highlight its utility in investigating galectin-mediated pathways, such as cancer immunotherapy (enhancing anti-tumor immunity) and managing chronic inflammation (e.g., in autoimmune disorders). Additionally, GAL9B shows promise in antiviral research, as it can bind to viral glycoproteins, inhibiting pathogens like HIV.
Despite its potential, challenges remain, including understanding tissue-specific functions and optimizing therapeutic delivery. Ongoing research aims to unravel GAL9B's pleiotropic roles and translate findings into targeted therapies for immune-related diseases and cancer.
×
